

<p style="text-align: center; font-weight: bold; font-size: 1.2em;">Examiner-Initiated Interview Summary</p>	<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; padding: 2px;">Application No. 10/042,421</td> <td style="width: 50%; padding: 2px;">Applicant(s) SACKSTEIN, ROBERT</td> </tr> <tr> <td style="padding: 2px;">Examiner Phillip Gambel</td> <td style="padding: 2px;">Art Unit 1644</td> </tr> </table>	Application No. 10/042,421	Applicant(s) SACKSTEIN, ROBERT	Examiner Phillip Gambel	Art Unit 1644
Application No. 10/042,421	Applicant(s) SACKSTEIN, ROBERT				
Examiner Phillip Gambel	Art Unit 1644				

All Participants:

(1) Phillip Gambel.

(2) Sheridan Snedden.

Date of Interview: 29 July 2010

Type of Interview:

☒ Telephonic

☐ Video Conference

☐ Personal (Copy given to: ☐ Applicant ☐ Applicant's representative)

Exhibit Shown or Demonstrated: ☐ Yes ☐ No

If Yes, provide a brief description: _____

Status of Application: _____

(3) _____

(4) _____

Time: _____

Part I.

Rejection(s) discussed:

Claims discussed:

pending/proposed

Prior art documents discussed:

Part II.

SUBSTANCE OF INTERVIEW DESCRIBING THE GENERAL NATURE OF WHAT WAS DISCUSSED:

See Continuation Sheet

Part III.

☒ It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview directly resulted in the allowance of the application. The examiner will provide a written summary of the substance of the interview in the Notice of Allowability.

☐ It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview did not result in resolution of all issues. A brief summary by the examiner appears in Part II above.

/Phillip Gambel/

Primary Examiner, Art Unit 1644

(Applicant/Applicant's Representative Signature – if appropriate)

Continuation of Substance of Interview including description of the general nature of what was discussed: examiner invited applicant to amend the claims to recite "glycosylated CD44 polypeptides" to clarify the claims and to place application in condition for allowance. examiner/applicant agreed for submission of claims drawn to immunoglobulin fusion proteins and compositions..